Towa Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	269,922	259,594	227,934	208,859	165,615	154,900
Revenue Growth (YoY)	6.54%	13.89%	9.13%	26.11%	6.92%	40.33%
Cost of Revenue	170,816	164,865	146,551	136,145	95,429	89,448
Gross Profit	99,106	94,729	81,383	72,714	70,186	65,452
Selling, General & Admin	58,451	54,954	50,405	51,825	39,381	34,842
Research & Development	16,212	16,212	13,242	15,265	11,488	10,642
Operating Expenses	74,983	71,486	63,735	67,199	51,648	45,523
Operating Income	24,123	23,243	17,648	5,515	18,538	19,929
Interest Expense	-2,146	-1,627	-947	-635	-230	-190
Interest & Investment Income	291	232	106	25	14	29
Currency Exchange Gain (Loss)	1,119	1,992	1,593	1,181	795	770
Other Non Operating Income (Expenses)	3,738	1,051	527	905	725	527
EBT Excluding Unusual Items	27,125	24,891	18,927	6,991	19,842	21,065
Gain (Loss) on Sale of Investments	-11	-38	-222	-20	-563	-45
Gain (Loss) on Sale of Assets	77	230	225	-46	96	97
Asset Writedown	1,258	1,247	5,550	-2,282	2,896	-2,388
Other Unusual Items	-1	-1	-21	-38	-26	-1
Pretax Income	28,448	26,329	24,459	4,605	22,245	18,728
Income Tax Expense	7,004	7,343	8,286	2,404	6,331	4,770
Net Income	21,444	18,986	16,173	2,201	15,914	13,958
Net Income to Common	21,444	18,986	16,173	2,201	15,914	13,958
Net Income Growth	11.23%	17.39%	634.80%	-86.17%	14.01%	-3.76%
Shares Outstanding (Basic)	49	49	49	49	49	49
Shares Outstanding (Diluted)	49	49	49	49	50	51
Shares Change (YoY)	0.01%	0.01%	-0.00%	-2.19%	-1.86%	-3.57%
EPS (Basic)	435.61	385.70	328.58	44.72	323.35	283.62
EPS (Diluted)	435.61	385.70	328.58	44.72	316.19	271.93
EPS Growth	11.22%	17.38%	634.82%	-85.86%	16.28%	-0.25%
Free Cash Flow	6,338	-5,335	-29,639	-26,187	10,989	2,871
Free Cash Flow Per Share	128.75	-108.38	-602.17	-532.02	218.36	55.99
Dividend Per Share	80.000	70.000	60.000	60.000	57.000	44.000
Dividend Growth	33.33%	16.67%	-	5.26%	29.54%	-
Gross Margin	-	36.49%	35.70%	34.82%	42.38%	42.25%
Operating Margin	8.94%	8.95%	7.74%	2.64%	11.19%	12.87%
Profit Margin	7.95%	7.31%	7.09%	1.05%	9.61%	9.01%
Free Cash Flow Margin	2.35%	-2.05%	-13.00%	-12.54%	6.64%	1.85%
EBITDA	46,246	43,342	35,536	24,924	29,492	30,354
EBITDA Margin	-	16.70%	15.59%	11.93%	17.81%	19.60%
D&A For EBITDA	22,123	20,099	17,888	19,409	10,954	10,425
EBIT	24,123	23,243	17,648	5,515	18,538	19,929
EBIT Margin	-	8.95%	7.74%	2.64%	11.19%	12.87%
Effective Tax Rate	-	27.89%	33.88%	52.20%	28.46%	25.47%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.